CA3092362A1 - Composes de picolinamide - Google Patents

Composes de picolinamide Download PDF

Info

Publication number
CA3092362A1
CA3092362A1 CA3092362A CA3092362A CA3092362A1 CA 3092362 A1 CA3092362 A1 CA 3092362A1 CA 3092362 A CA3092362 A CA 3092362A CA 3092362 A CA3092362 A CA 3092362A CA 3092362 A1 CA3092362 A1 CA 3092362A1
Authority
CA
Canada
Prior art keywords
cancer
compound
cyclobutyl
pharmaceutically acceptable
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3092362A
Other languages
English (en)
Inventor
David Andrew Powell
Jeffrey Roger Roppe
Thomas Jon Seiders
Jimyue Ding
Tao Sheng
Jason Duarte Jacintho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tempest Therapeutics Inc
Original Assignee
Tempest Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tempest Therapeutics Inc filed Critical Tempest Therapeutics Inc
Publication of CA3092362A1 publication Critical patent/CA3092362A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux composés de formule (I) et des sels pharmaceutiquement acceptables, des solvates, des solvates du sel de ceux-ci, utiles dans la prévention (par exemple, retarder l'apparition ou réduire le risque de développement) et le traitement (par exemple, maîtriser, soulager ou ralentir la progression) du cancer, y compris le glioblastome, le cancer de l'os, le cancer de la tête et du cou, le mélanome, le carcinome basocellulaire, le carcinome des cellules squameuses, l'adénocarcinome, le cancer buccal, le cancer de l'sophage, le cancer gastrique, le cancer du côlon, le cancer de la vessie, le carcinome hépatocellulaire, le carcinome des cellules rénales, le cancer du pancréas, le cancer de l'ovaire, le cancer du col de l'utérus, le cancer du poumon, le cancer du sein et le cancer de la prostate. Les composés de formule (I), ou leurs sels pharmaceutiquement acceptables, sont des inhibiteurs de l'IDO.
CA3092362A 2017-10-19 2018-10-18 Composes de picolinamide Abandoned CA3092362A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762574583P 2017-10-19 2017-10-19
US62/574,583 2017-10-19
PCT/US2018/056539 WO2019079614A1 (fr) 2017-10-19 2018-10-18 Composés de picolinamide

Publications (1)

Publication Number Publication Date
CA3092362A1 true CA3092362A1 (fr) 2019-04-25

Family

ID=66174302

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3092362A Abandoned CA3092362A1 (fr) 2017-10-19 2018-10-18 Composes de picolinamide

Country Status (3)

Country Link
EP (1) EP3735410A4 (fr)
CA (1) CA3092362A1 (fr)
WO (1) WO2019079614A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022026397A2 (pt) * 2020-06-23 2023-03-14 Chemocentryx Inc Métodos para tratar câncer usando derivados de amida de heteroaril-bifenila

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006012227A2 (fr) * 2004-06-24 2006-02-02 Incyte Corporation Composes amido et utilisations de ces derniers en tant que produits pharmaceutiques
US8034940B2 (en) * 2006-08-09 2011-10-11 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
EP2493862B1 (fr) * 2009-10-28 2016-10-05 Newlink Genetics Corporation Dérivés imidazole comme inhibiteurs de l'ido
EP2651930B1 (fr) * 2010-12-16 2015-10-28 Boehringer Ingelheim International GmbH Inhibiteurs biarylamide de production de leukotriènes
CA2905452A1 (fr) * 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Inhibiteurs de l'indoleamine 2,3-dioxygenase (ido)
JP6510068B2 (ja) * 2015-11-27 2019-05-08 大鵬薬品工業株式会社 新規なビフェニル化合物又はその塩

Also Published As

Publication number Publication date
WO2019079614A1 (fr) 2019-04-25
EP3735410A4 (fr) 2021-11-03
EP3735410A1 (fr) 2020-11-11

Similar Documents

Publication Publication Date Title
US11638704B2 (en) Bicyclic compounds and their use in the treatment of cancer
TWI761315B (zh) 醫藥化合物
CN109475520B (zh) 包含ep4拮抗剂和免疫检查点抑制剂的组合
JP2021514982A (ja) インドール−２−カルボニル化合物及びｂ型肝炎治療のためのそれらの使用
JP2021503458A (ja) 新規のジヒドロイソキサゾール化合物及びｂ型肝炎治療のためのそれらの使用
JP2021520342A (ja) 免疫調節物質、組成物及びそれらの方法
JP2021507906A (ja) 抗ウイルス剤としての融合三環式ピラゾロ−ジヒドロピラジニル−ピリドン化合物
AU2019255717B2 (en) Bicyclic carboxamides and methods of use thereof
EA032754B1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
WO2021067606A1 (fr) Composés ciblant brm et procédés d'utilisation associés
KR20190141145A (ko) 피리미딘일-피리딜옥시-나프틸 화합물 및 ire1-관련 질환 및 장애 치료 방법
CA3117850A1 (fr) Inhibiteurs de ret, compositions pharmaceutiques et utilisations associees
CN110857293A (zh) 一种新型的喹啉衍生物抑制剂
US11066405B2 (en) Bicyclic compounds and their use in the treatment of cancer
CA3092362A1 (fr) Composes de picolinamide
WO2020123426A1 (fr) Amides d'aminoazine
KR20240093673A (ko) 삼환계 gpr65 조절제
EA044307B1 (ru) Иммуномодуляторы, их композиции и способы применения
TW202432535A (zh) Pd‐1/pd‐l1抑制劑

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20230419

FZDE Discontinued

Effective date: 20230419